

17th September, 2024

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra
(East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Press Release – Piramal Pharma Limited (‘the Company’) commitment to reduce Greenhouse Gas (GHG) emissions, validated and approved by Science Based Targets initiative (SBTi)

Dear Sir / Madam,

This is to inform you that the Company has received SBTi approval for its commitment to reduce Scope 1 and 2 GHG emissions by 42% and Scope 3 by 25% by FY 2030. Piramal Pharma is now the third global pharmaceutical company in India to have its targets validated and approved from SBTi.

A copy of Press Release in this regard is enclosed for your ready reference.

Kindly take the above on record.

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Encl.: a/a

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

- *Piramal Pharma has committed to reduce its GHG emissions for Scope 1, 2, and 3 by 2030*

Mumbai, India, September 17, 2024 – Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, has embarked on its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company's near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma's core purpose of *'Doing Well and Doing Good,'* driving its business strategies and strengthening the company's commitment to making consistent, measurable progress toward a more sustainable future.

Piramal Pharma Limited has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year. Piramal Pharma Limited has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and use of sold products 25% within the same timeframe. This makes Piramal Pharma the third global pharmaceutical company in India to receive approval from the SBTi.

Speaking on this pivotal step forward, Nandini Piramal, Chairperson, Piramal Pharma Limited, said, *"Sustainability is at the heart of our business strategy, and the approval from SBTi reinforces our ongoing commitment to reducing our GHG emissions and aligning with global climate action goals. This is a critical step in our broader sustainability roadmap, and we are committed to doing our part in driving meaningful environmental change across the pharmaceutical industry. To further reinforce our commitment, we are also in the process of developing a comprehensive Carbon Reduction Plan, which will be unveiled soon. While we have come a long way, in many respects, our sustainability journey is just beginning."*

The Science Based Targets initiative (SBTi), a collaboration between the Carbon Disclosure Project (CDP), United Nations Global Compact (UNGC), World Resources Institute (WRI), and World Wide Fund (WWF), guides companies in reducing their greenhouse gas emissions. It provides a clear pathway for future-proof growth by specifying how much and how quickly emissions must be cut to limit global warming to well below 1.5°C above pre-industrial levels.

For more information about Piramal Pharma's GHG reduction efforts and its commitment to the Science Based Targets initiative, please visit <https://sciencebasedtargets.org/target-dashboard/>.

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION



therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: [Piramal Pharma | LinkedIn](#)

Media contact

Madiha Vahid

Madiha.Vahid@piramal.com

For queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

Gagan.borana@piramal.com

*Includes one facility through minority investment in Yapan Bio